5.24

1.75% 0.09

After Hours: 5.34 0.10 +1.91%

Atara Biotherapeutics Inc (ATRA)

Overview News Price History Option Chain Financials Why ATRA Down? Discussions Forecast

Atara Biotherapeutics Inc stock is traded at $5.24, with a volume of 53,532. It is up +1.75% in the last 24 hours and down -19.38% over the past month. Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.

Previous Close:

$5.15

Open:

$5.14

24h Volume:

53,532

Relative Volume:

0.15

Market Cap:

$42.85M

Revenue:

$120.77M

Net Income/Loss:

$32.69M

P/E Ratio:

1.7978

EPS:

2.9146

Net Cash Flow:

$-50.94M

1W Performance:

+4.59%

1M Performance:

-19.38%

6M Performance:

-65.71%

1Y Performance:

-12.37%

1-Day Range:

$5.11

$5.38

1-Week Range:

$4.44

$5.38

52-Week Range:

$3.92

$19.14

Atara Biotherapeutics Inc Stock (ATRA) Company Profile

Name

Atara Biotherapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

805-623-4211

Address

1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA

Employee

Twitter

@Atarabio

Next Earnings Date

2026-03-20

Latest SEC Filings

ATRA's Discussions on Twitter

Compare ATRA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ATRA Atara Biotherapeutics Inc	5.24	42.12M	120.77M	32.69M	-50.94M	2.9146
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-13-26	Downgrade	Canaccord Genuity	Buy → Hold
Nov-09-23	Downgrade	Evercore ISI	Outperform → In-line
Nov-09-23	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-09-23	Downgrade	Mizuho	Buy → Neutral
Jul-20-22	Downgrade	Citigroup	Neutral → Sell
Jul-13-22	Downgrade	JP Morgan	Overweight → Neutral
Jul-13-22	Downgrade	Stifel	Buy → Hold
May-10-22	Downgrade	Citigroup	Buy → Neutral
May-13-21	Upgrade	JP Morgan	Neutral → Overweight
Dec-09-20	Downgrade	Citigroup	Buy → Neutral
Dec-08-20	Reiterated	H.C. Wainwright	Buy
Nov-10-20	Reiterated	H.C. Wainwright	Buy
Jun-30-20	Initiated	Evercore ISI	Outperform
Jun-15-20	Initiated	H.C. Wainwright	Buy
Apr-23-20	Upgrade	Citigroup	Neutral → Buy
Nov-08-19	Downgrade	JP Morgan	Overweight → Neutral
Sep-27-19	Downgrade	Goldman	Neutral → Sell
Sep-16-19	Downgrade	Jefferies	Buy → Hold
Jun-04-19	Upgrade	Citigroup	Sell → Neutral
May-30-19	Initiated	ROTH Capital	Buy
May-23-19	Initiated	Stifel	Buy
Jan-23-19	Initiated	Mizuho	Buy
Apr-10-18	Initiated	JP Morgan	Overweight
Mar-16-18	Initiated	Guggenheim	Neutral
Mar-05-18	Reiterated	Jefferies	Buy
Feb-28-18	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Feb-15-18	Downgrade	Citigroup	Neutral → Sell
Jan-03-18	Upgrade	Citigroup	Sell → Neutral
Oct-06-17	Resumed	Goldman	Neutral

View All

Atara Biotherapeutics Inc Stock (ATRA) Latest News

12:46 PM

ROSEN, A LEADING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel ... - Caledonian Record

12:46 PM

12:45 PM

ROSEN, A LEADING LAW FIRM, Encourages Atara - GlobeNewswire

12:45 PM

09:03 AM

ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

09:03 AM

Apr 14, 2026

Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA - ChartMill

Apr 14, 2026

ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit - Lelezard

Apr 14, 2026

ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire

Apr 14, 2026

ATRA Shareholder Alert: May 22, 2026 Lead Plaintiff Deadline in Atara Biotherapeutics, Inc. Securities Class Action Lawsuit — The Gross Law Firm - Morningstar

Apr 14, 2026

Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire

Apr 14, 2026

2026-04-14 | ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:ATRA | Press Release - Stockhouse

Apr 14, 2026

ATRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Apr 14, 2026

Apr 13, 2026

Class Action Filed Against Atara Biotherapeutics Over Alleged Securities Fraud - National Today

Apr 13, 2026

Class Action Filed Against Atara Biotherapeutics, Inc. (ATRA) Seeking Recovery for Investors – Contact Levi & Korsinsky - GlobeNewswire

Apr 13, 2026

Atara Biotherapeutics Faces Securities Fraud Lawsuit - National Today

Apr 13, 2026

Activity Recap: Is Atara Biotherapeutics Inc impacted by rising ratesMarket Trend Summary & Verified Technical Signals - baoquankhu1.vn

Apr 13, 2026

Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) - GlobeNewswire

Apr 13, 2026

Bronstein, Gewirtz & Grossman LLC Urges Atara - GlobeNewswire

Apr 13, 2026

Portnoy Law Firm Announces Class Action on Behalf of Atara Biotherapeutics, Inc. Investors - WFMZ.com

Apr 13, 2026

Buybacks Report: What are analysts price targets for Atara Biotherapeutics IncInsider Selling & Precise Trade Entry Recommendations - baoquankhu1.vn

Apr 13, 2026

Apr 12, 2026

ROSEN, A TOP RANKED LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors with Losses in ... - Bluefield Daily Telegraph

Apr 12, 2026

ROSEN, A TOP RANKED LAW FIRM, Encourages Atara - GlobeNewswire

Apr 12, 2026

2026-04-12 | ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:ATRA | Press Release - Stockhouse

Apr 12, 2026

Apr 10, 2026

Atara Biotherapeutics, Inc.Common Stock (NQ: ATRA - The Chronicle-Journal

Apr 10, 2026